FGF21 and type 1 diabetes mellitus: The application of a half-life extended form of FGF21 (FGF21-PEG) has been demonstrated to normalize plasma glucose levels in streptozotocin-treated mice, a model of type 1 diabetes mellitus (T1DM), without reinstating pancreatic β-cell function.